Seattle Genetics Inc (SGEN.OQ)
21 Mar 2018
Tue, Mar 20 2018
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, making it the first new treatment in over 40 years.
* Company expects $1 billion in Adcetris sales within few years
* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA
U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients.
* UNUM THERAPEUTICS INC SEES IPO OF 5.8 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $12.00 AND $14.00 PER SHARE - SEC FILING
* SEATTLE GENETICS APPOINTS DR. ALPNA SETH TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES
BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION
BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration
* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:
* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.
- Your Daily Pharma Scoop: Arena Soars, Roche Data, GlaxoSmithKline Commences Study
- Unum Therapeutics Updates Proposed IPO Terms
- JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness
- JF's Core Biotech Buys Edition 1 Volume 6: Buying Weakness In 2 Beaten Down Stocks
- 3 Things In Biotech, March 8: A Tale Of 3 New Trials
- Your Daily Pharma Scoop: Esperion's Positive Data, Adamis Results, Mesoblast Gets Funding